VaxDome

VaxDome is a Fort Worth, Texas-based biotechnology company focused on developing a novel class of broad-spectrum, mutation-agnostic, and noninvasive vaccines and antivirals. The company's core technology is its proprietary zIFV platform, which rapidly transforms a selected influenza virus strain into an intranasally delivered, antigen-agnostic antiviral-vaccine hybrid. This hybrid approach is designed to combine immediate antiviral activity with durable immune protection by mobilizing rapid innate and adaptive immune responses without inducing harmful systemic inflammation. VaxDome is currently advancing its lead candidates toward clinical trials in collaboration with its manufacturing partner, Matica Biotechnology, targeting both viral infectious diseases (such as influenza) and oncology indications like lung cancer.